The newly published review 'Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood' describes the current status of assays for PINP and β-CTX in blood, as well as the plans for and ongoing progress towards the achievement of harmonization or standardization of commercial assays for these reference markers.
Primary amoebic meningoencephalitis (PAM), a deadly disease caused by the "brain-eating amoeba" Naegleria fowleri, is becoming more common in some areas of the world, and it has no effective treatment. Now, researchers reporting in ACS Chemical Neuroscience have found that a compound isolated from the leaves of a traditional medicinal plant, Inula viscosa or "false yellowhead," kills the amoebae by causing them to commit cell suicide in lab studies, which could lead to new treatments.
The body's immune system is the first line of defense against infections like bacteria, viruses or cancers. Some cancers, however, have developed the art of molecular deception to avoid destruction by the body's immune system. Now, a University of Missouri researcher might have found a new way to help the body's immune system get past that deception and destroy the cancer.
Researchers at Karolinska Institutet in Sweden have developed, in collaboration with researchers in Germany and the US, new small antibodies, also known as nanobodies, which prevent the SARS-CoV-2 coronavirus from entering human cells. The research study, published in Science, shows that a combined nanobody had a particularly good effect - even if the virus mutated. According to the researchers, the nanobodies have the potential to be developed into a treatment for COVID-19.
In a paper published in Molecular Frontiers Journal, researchers from Cambridge, Massachusetts and Bangalore, India study the effectiveness of FEND product to significantly improve airway hygiene by reducing and suppressing respiratory droplets potentially containing airborne pathogens and other contaminants.
Acta Pharmaceutica Sinica B Volume 10, Issue 12 Publishes The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association, Acta Pharmaceutica Sinica B (APSB) is a monthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences -- including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.
Acta Pharmaceutica Sinica B Volume 10, Issue 11 Publishes Special Issue: Tumor Microenvironment and Drug Delivery Guest Editors: Huile Gao, West China School of Pharmacy, Sichuan University, Chengdu, China; Zhiqing Pang, Fudan University, Shanghai, China and Wei He, China Pharmaceutical University, Nanjing, China
Currently there's no treatment for botulism once the toxin gets into neurons. This novel treatment neutralized the toxin with a second, modified botulinum toxin that delivered a mini antibody into the cells - reversing paralysis in mice.
Across the world, health care workers and high-risk groups are beginning to receive COVID-19 vaccines, offering hope for a return to normalcy amidst the pandemic. However, the vaccines authorized for emergency use in the U.S. require two doses to be effective, which can create problems with logistics and compliance. Now, researchers reporting in ACS Central Science have developed a nanoparticle vaccine that elicits a virus-neutralizing antibody response in mice after only a single dose.
POSTECH-UNIST joint research team finds ways to control the surface texture of nanostructures.